Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.

We recently published a list of 10 Firms End 2024 Stronger With Impressive Gains. In this article, we are going to take a ...

Moderna Inc (MRNA) stock saw a modest uptick, ending the day at $41.58 which represents a slight increase of $2.20 or 5.59% from the prior close of $39.38. The stock opened at $39.71 and touched a low ...

Moderna is a contrarian play for 2025, despite a rough 2024 as one of the worst-performing Nasdaq-100 stocks. Click here to ...

Despite being a pioneer in developing one of the first and most widely used COVID-19 vaccines, shares of Moderna MRNA have ...

Moderna 's ( MRNA 3.13%) wild success in the COVID-19 vaccine market has worn off. The company's revenue, earnings, and stock ...

Now, China-based CARsgen has shared pivotal results from the latter portion of a phase 1/2 study evaluating the therapy for ...

Moderna Inc (MRNA) stock saw a decline, ending the day at $40.13 which represents a decrease of $-0.30 or -0.74% from the prior close of $40.43. The stock opened at $40.35 and touched a low of $39.79 ...

Key Takeaways U.S. equities were closing out 2024 by edging lower at midday after opening the session higher.Berkshire ...

According to Benzinga Pro, Moderna's peer group average for short interest as a percentage of float is 4.49%, which means the ...

Shares of Moderna Inc. MRNA shed 1.87% to $39.38 Monday, on what proved to be an all-around grim trading session for the ...

We recently published a list of 14 Stocks That Jim Cramer Recently Talked About. In this article, we are going to take a look ...